Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
It would be really interesting to know whether the properties of FF (in all their guises) have had any positive effect on any of us who take the tablets regularly. I guess it wouldn't be a conclusive study but at least it would be quite easy for the Company to do a straw poll of all of us monthly subscribers to identify how many of us have felt the full force of the Covid virus.
Your recent posting about the additional Patents in the US can only be good news and can only indicate a potentially growing market on the other side of the pond. TBH I can't understand why this news didn't warrant an RNS.
The initial Abstract posted on the Provexis website on 25th June 2021 seems to indicate that fruitflow could potentially control a wider range of conditions.
The latest two abstracts (one in the UK and one in China) seems to indicate that Fruitflow might have a positive impact in the Covid environment - maybe we might also see some further investigations/trials either in this country or in China and maybe pointing to the anti thrombosis benefits of Fruitflow.
Who knows and as you say - only time will tell.
Gixer,
Some of your "research" findings have been amazing and we all have to thank you for that. In all probability they have kept me locked in as a LTH and, at times like now, have even tempted me to by more.
I am not trying to ramp or deramp the Company but some of the recent "stuff" that has been released has been interesting to say the least:
1
Alfista,
You have explained the concept very well. However, the thing that I have never understood is the size of the bid offer spread that they use.
For example, the price quoted yesterday was: Bid 0.84 and Offer 1.0. The Bid/Offer spread was 19%. In fact, if you tried to trade yesterday (as I did) you will have noted that the actual trading prices were: Bid 0.84 and Offer 0.95. The actual Bid/Offer spread was 13%. However, I was completely put off trading because I didn;t want to look at an immediate 13% loss in the value of my investment.
Whichever you consider, the Bid/Offer spread that is quoted is still far too high to encourage investors to trade - and for the last week certainly there has been minimum volume whilst the spreads have been that wide.
On the other hand I have plotted significantly higher volumes when the spreads have been tightened.
Surely the MMs job is to encourage volume - they won't make any money unless shares are trading and we won't get a liquid market in the stock until that happens.
I suspect that that is for two reasons:
1 The dearth of news (even though there seems to be a lot going on in the background!!!)
2 The odd actions of the MMs in setting the share price, together with the wide bid/ask spreads. The spreads are beginning to make this an illiquid stock - whenever the spreads have been narrowed, shares have been traded - it is almost as if the MMs don;t want to trade shares
I understand that AGILE comes with really positive upsides (funding and fast track access to the clinical trial process) but aren't there also a series of downsides ( sharing of IP and regulation on sales price of the drug if the trials are successful) ???
Gixer,
From the same interims it was stated that ByHealth were planning to undertake 9 separate studies (as part of the Blue Cap application process). It is really frustrating that the Company have not provided any further updates on progress since January. Have you been able to eek out any additional information on this?
I was impressed by the statement that you extracted from the ByHealth Website: "the company has taken "Fruitflow® (water-soluble tomato concentrate)" as its main direction, focusing on the development of new functional products that help maintain cardiovascular health." I presume that this was a translation from the original Chinese but it nevertheless shows a real drive by ByHealth in our direction.
I was also impressed by the abstract recently posted on the Provexis website, indicating a potential number of other uses for WSTE and possibly even indicative of use within mainstream medicine.
Like Krusty, I am feeling much more confident in this share than I have for a number of years - but, my god, it is a frustrating share to follow with its lack of updates.
The activity in the market over the last few days (two weeks) has been a little bizarre and quite discomforting. So many very very small trades all posted at the same times. I might have understood if this had happened once, or maybe twice, but for it to be happening on so many regular occasions is beyond logic.
Does anyone have any rational reason why this is happening.
Gixer (or anybody for that matter)
Does anybody have any clue as to why the income levels for H1 are so much better than the income levels for H2????
This isn't simply an observation of the latest R&A - this has happened consistently for the last 3 years and it applies to both the SSM Alliance Agreement incomes and the FF+ incomes. It is bizarre and I would really like to understand why there is such a substantial difference.
Can anybody help to explain.
Slam